$MYO
MYOMO, INC.

2020 Q1 Form 10-K Financial Statement

#000156459021012068 Filed on March 10, 2021

View on sec.gov

Income Statement

Concept 2020 Q1 2020 2019 Q4
Revenue $1.008M $7.583M $1.521M
YoY Change 21.45% 97.6% 70.95%
Cost Of Revenue $318.7K $2.600M $424.7K
YoY Change 80.86% 83.03% 87.75%
Gross Profit $689.5K $4.983M $1.096M
YoY Change 5.45% 106.17% 65.22%
Gross Profit Margin 68.39% 65.71% 72.08%
Selling, General & Admin $3.605M $13.82M $3.234M
YoY Change 28.68% 20.54% 12.74%
% of Gross Profit 522.84% 277.27% 295.09%
Research & Development $507.0K $1.669M $442.5K
YoY Change -5.29% -4.59% -16.45%
% of Gross Profit 73.52% 33.5% 40.37%
Depreciation & Amortization $26.39K $105.4K $24.44K
YoY Change 22.01% 10.78% 17.22%
% of Gross Profit 3.83% 2.11% 2.23%
Operating Expenses $4.112M $15.49M $3.677M
YoY Change 23.23% 17.21% 8.19%
Operating Profit -$3.422M -$10.50M -$2.581M
YoY Change 27.57% -2.71% -5.64%
Interest Expense $135.2K -$352.0K -$180.7K
YoY Change 216.17% 30777.19% -519.53%
% of Operating Profit
Other Income/Expense, Net -$379.0K -$1.061M
YoY Change -547.22% -1394.27%
Pretax Income -$3.801M -$11.56M -$2.762M
YoY Change 46.32% 7.94% 2.58%
Income Tax $613.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.802M -$11.56M -$2.762M
YoY Change 46.34% 7.94% 2.58%
Net Earnings / Revenue -377.13% -152.49% -181.59%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.137M -$3.473M -$4.812M
COMMON SHARES
Basic Shares Outstanding 17.20M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2020 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.73M $12.24M $4.465M
YoY Change 48.66% 174.13% -31.73%
Cash & Equivalents $13.80M $12.24M $4.465M
Short-Term Investments
Other Short-Term Assets $937.2K $572.7K $820.2K
YoY Change 19.43% -30.18% 17.97%
Inventory $602.9K $707.1K $439.5K
Prepaid Expenses
Receivables $299.3K $924.9K $424.3K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $15.57M $14.45M $6.149M
YoY Change 45.21% 134.91% -21.91%
LONG-TERM ASSETS
Property, Plant & Equipment $139.2K $263.8K $155.0K
YoY Change -19.57% 70.23% -17.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $207.0K $294.2K
YoY Change 0.0% 34.0%
Total Long-Term Assets $346.2K $263.8K $449.2K
YoY Change -8.91% -41.27% 10.35%
TOTAL ASSETS
Total Short-Term Assets $15.57M $14.45M $6.149M
Total Long-Term Assets $346.2K $263.8K $449.2K
Total Assets $15.91M $14.71M $6.599M
YoY Change 43.36% 122.92% -20.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.024M $180.5K $450.1K
YoY Change 94.79% -59.9% 5.48%
Accrued Expenses $1.604M $2.687M $1.288M
YoY Change 104.44% 108.54% -2.15%
Deferred Revenue $27.34K $40.00
YoY Change -67.5% -99.96%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.427M $0.00 $1.764M
YoY Change -100.0%
Total Short-Term Liabilities $4.128M $2.870M $3.884M
YoY Change 161.53% -26.11% 109.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $889.0K
YoY Change -100.0%
Other Long-Term Liabilities $1.500K $274.7K $1.500K
YoY Change 18213.33%
Total Long-Term Liabilities $1.500K $274.7K $889.0K
YoY Change -69.15%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.128M $2.870M $3.884M
Total Long-Term Liabilities $1.500K $274.7K $889.0K
Total Liabilities $4.129M $3.144M $4.774M
YoY Change 161.63% -34.13% 157.26%
SHAREHOLDERS EQUITY
Retained Earnings -$56.13M
YoY Change 23.93%
Common Stock $71.72M $57.96M
YoY Change 24.65% 12.06%
Preferred Stock
YoY Change
Treasury Stock (at cost) $6.464K
YoY Change 0.0%
Treasury Stock Shares
Shareholders Equity $11.78M $11.57M $6.426M
YoY Change
Total Liabilities & Shareholders Equity $15.91M $14.71M $6.599M
YoY Change 43.36% 122.92% -20.32%

Cashflow Statement

Concept 2020 Q1 2020 2019 Q4
OPERATING ACTIVITIES
Net Income -$3.802M -$11.56M -$2.762M
YoY Change 46.34% 7.94% 2.58%
Depreciation, Depletion And Amortization $26.39K $105.4K $24.44K
YoY Change 22.01% 10.78% 17.22%
Cash From Operating Activities -$2.445M -$9.033M -$2.644M
YoY Change -21.63% -12.66% 5.22%
INVESTING ACTIVITIES
Capital Expenditures $7.878K $45.75K -$13.73K
YoY Change 45.78% -12.0% 44.53%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$7.878K -$45.75K -$13.73K
YoY Change 45.78% -12.0% 44.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $13.50M
YoY Change 141.07%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 11.71M 16.78M 2.795M
YoY Change 101.34% 101.73% -9382.46%
NET CHANGE
Cash From Operating Activities -2.445M -9.033M -2.644M
Cash From Investing Activities -7.878K -45.75K -13.73K
Cash From Financing Activities 11.71M 16.78M 2.795M
Net Change In Cash 9.261M 7.701M 137.1K
YoY Change 243.92% -471.06% -105.37%
FREE CASH FLOW
Cash From Operating Activities -$2.445M -$9.033M -$2.644M
Capital Expenditures $7.878K $45.75K -$13.73K
Free Cash Flow -$2.453M -$9.079M -$2.630M
YoY Change -21.51% -12.65% 5.07%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2869705
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
888961
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1140
CY2020 us-gaap Gross Profit
GrossProfit
4982996
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1669188
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1749509
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11462457
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
118060
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3883529
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
155148
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1495
CY2019Q4 us-gaap Liabilities
Liabilities
4773985
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
122706
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4593184
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
57
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
57957097
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
574524
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4593157
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
574497
CY2020Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
27
CY2019Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
27
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7583371
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3837730
CY2020 us-gaap Cost Of Revenue
CostOfRevenue
2600375
CY2019 us-gaap Gross Profit
GrossProfit
2416963
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-10795003
CY2019 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
-797637
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11510646
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
553782
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4465455
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
424287
CY2019Q4 us-gaap Inventory Net
InventoryNet
439533
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
820206
CY2019Q4 us-gaap Assets Current
AssetsCurrent
6149481
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
95023
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
168784
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
18289
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
457
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
79273964
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12690
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67689893
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56125982
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
6464
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
6464
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
11565374
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1824708
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14709782
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6598693
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
676703
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
36169
CY2019 us-gaap Cost Of Revenue
CostOfRevenue
1420767
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13816494
CY2020 us-gaap Operating Expenses
OperatingExpenses
15485682
CY2019 us-gaap Operating Expenses
OperatingExpenses
13211966
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
218803
CY2019 us-gaap Interest Expense Debt
InterestExpenseDebt
113631
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-709222
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1061225
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
81994
CY2020 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
-670632
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12234543
CY2019 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
194485
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-10502686
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
15
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
161298
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12241261
CY2020 myo Common Stock Issued For Warrants Exercised
CommonStockIssuedForWarrantsExercised
161250
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8318469
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3329868
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12690
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-12690
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11576601
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10713009
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
6425885
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5603829
CY2019 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-80250
CY2019 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-72
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15
CY2019 myo Warrants Issued As Offering Costs And Recorded As Derivative Liability
WarrantsIssuedAsOfferingCostsAndRecordedAsDerivativeLiability
196236
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
907993
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13475535
CY2020 myo Proceeds From Issuance Of Prefunded Warrants In Conjunction With Public Offering
ProceedsFromIssuanceOfPrefundedWarrantsInConjunctionWithPublicOffering
48
CY2020 myo Proceeds From Issuances Under At Market Sales Facility Value
ProceedsFromIssuancesUnderAtMarketSalesFacilityValue
4917575
CY2020 myo Issuances Of Common Stock Value Repay Debt
IssuancesOfCommonStockValueRepayDebt
2150405
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-1852
CY2020 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
1
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
614302
CY2020 us-gaap Unrealized Loss On Foreign Currency Derivatives Before Tax
UnrealizedLossOnForeignCurrencyDerivativesBeforeTax
12690
CY2020 myo Offering Cost From Sale Of Shares
OfferingCostFromSaleOfShares
1499370
CY2019 myo Offering Cost From Sale Of Shares
OfferingCostFromSaleOfShares
710572
CY2019 myo Prior Period Offering Cost From Sale Of Shares
PriorPeriodOfferingCostFromSaleOfShares
161253
CY2020 us-gaap Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
489
CY2019 us-gaap Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
1836
CY2020 us-gaap Profit Loss
ProfitLoss
-11563911
CY2019 us-gaap Profit Loss
ProfitLoss
-10713009
CY2020 us-gaap Depreciation
Depreciation
105382
CY2019 us-gaap Depreciation
Depreciation
95124
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
614302
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
907993
CY2020 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-547
CY2019 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-2481
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
9839
CY2020 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
161869
CY2019 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
58296
CY2020 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
3288
CY2019 us-gaap Inventory Write Down
InventoryWriteDown
-71265
CY2020 myo Fair Value Of Warrants And Derivative Liabilities
FairValueOfWarrantsAndDerivativeLiabilities
122706
CY2019 myo Fair Value Of Warrants And Derivative Liabilities
FairValueOfWarrantsAndDerivativeLiabilities
194485
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
18446
CY2019 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-9423
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
522944
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
42028
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
271545
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
213562
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-248464
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
163742
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-57987
CY2019 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
87265
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1217929
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
60742
CY2020 myo Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
1365
CY2020 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-401
CY2019 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2418
CY2020 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
118060
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2075339
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4540455
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6615794
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-106569
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9032896
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10341817
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45752
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
51991
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-45752
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-51991
CY2019 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
2788019
CY2020 us-gaap Repayments Of Debt
RepaymentsOfDebt
1703552
CY2020 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
255533
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
13504812
CY2019 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5603829
CY2020 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1855
CY2019 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
80322
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3
CY2020 myo Proceeds From At The Market Offering Net Of Offering Costs
ProceedsFromAtTheMarketOfferingNetOfOfferingCosts
5049551
CY2020 myo Proceeds From Payments Under Grants
ProceedsFromPaymentsUnderGrants
25852
CY2019 myo Proceeds From Payments Under Grants
ProceedsFromPaymentsUnderGrants
6928
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16780576
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-1122
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7700806
CY2020 myo Inventory Capitalized As Sales Demo Equipment
InventoryCapitalizedAsSalesDemoEquipment
2743
CY2019 myo Inventory Capitalized As Sales Demo Equipment
InventoryCapitalizedAsSalesDemoEquipment
17715
CY2020 us-gaap Property Plant And Equipment Transfers And Changes
PropertyPlantAndEquipmentTransfersAndChanges
2514
CY2020 myo Deferred Issuance Costs To Additional Paid In Capital Paid In Prior Period
DeferredIssuanceCostsToAdditionalPaidInCapitalPaidInPriorPeriod
161253
CY2020 us-gaap Stock Issued1
StockIssued1
2150405
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
172072
CY2019 myo Issuance Of Selling Agent Warrants
IssuanceOfSellingAgentWarrants
196236
CY2019 myo Put Option Bifurcated From Term Loan
PutOptionBifurcatedFromTermLoan
372827
CY2019 myo Conversion Of Accrued Interest To Principal
ConversionOfAccruedInterestToPrincipal
65270
CY2020 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 1 &#8212; Description of Business</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Myomo Inc. (&#8220;Myomo&#8221; or the Company&#8221;) is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro &#174; myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class&#160;II medical device. The Company sells the product to orthotics and prosthetics (O&amp;P) providers, the Veterans Health Administration (VA), rehabilitation hospitals, and through distributors. Recently, the Company has begun providing devices directly to patients and billing their insurance companies directly, utilizing the clinical services of O&amp;P providers for which they are paid a fee. The Company was incorporated in the State of Delaware on September&#160;1, 2004 and is headquartered in Cambridge, Massachusetts.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to an amended and restated certificate of incorporation, the Company is authorized to issue up to 125,000,000 shares of stock, consisting of 100,000,000 shares of common stock, par value $0.0001 and 25,000,000 shares of undesignated Preferred Stock, par value of $0.0001.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Shelf Registration Statement</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 2, 2018, the Company filed a Registration Statement on Form S-3 (the &#8220;Shelf&#8221;) with the Securities and Exchange Commission in relation to the registration of common stock, preferred stock, warrants and/or units or any combination thereof the Company (collectively, the &#8220;Securities&#8221;) having an aggregate price of up to $75 million, subject to the limitations of the Shelf. The Company simultaneously entered into an At Market Issuance Sales Agreement (the &#8220;ATM&#8221;) with B. Riley FBR, Inc., as sales agent, to provide for the offering, issuance and sale by the Company of up to an aggregate amount of $15 million of the Company&#8217;s common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf and subject to the limitations thereof. The Company shall pay to the sales agent cash commissions of 3.0% of the gross proceeds of sales of common stock under the ATM. The ATM was suspended following the Company&#8217;s follow-on public offering in February 2019 and reinstated in May 2020. See Note 7 &#8211; Preferred and Common Stock, for further information.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Follow-on Public Offerings</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company completed a follow-on offering of 1,660,000 shares of its common stock and 1,660,000 investor warrants to purchase one share of the Company&#8217;s common stock at a combined offering price of $7.00 per share.&nbsp;&nbsp;In addition, the Company sold 483,000 pre-funded warrants and 483,000 investor warrants to purchase one share of the Company&#8217;s common stock at a combined offering price of $6.999 per share. The offering generated approximately $13.5 million in net proceeds to the Company.&nbsp;&nbsp;See Note 7 &#8211; Preferred and Common Stock, for further information.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, the Company completed a follow-on offering of 151,417 shares of its common stock, including the underwriter&#8217;s exercise of its over-allotment option, generating net proceeds of approximately $5.6 million. See Note 7 &#8211; Common Stock, for further information.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Term Loan</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 22, 2019, the Company entered into a Note Purchase Agreement, Senior Note and Security Agreement (collectively, the &#8220;Term Loan&#8221;) with Chicago Venture Partners (&#8220;CVP &#8220;or &#8220;Lender&#8221;). Under the Term Loan, the Company received gross proceeds of $3.0 million, excluding fees and expenses. Including an original issue discount, the Company repaid the Lender $3.3 million.&nbsp;&nbsp;See Note 6 &#8211; Debt, for further information</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reverse Stock Split</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 30, 2020, we filed with the State of Delaware an amendment to our Eighth Amended and Restated Certificate of Incorporation for a one-for-thirty reverse split of our common stock. All share and per share information has been restated retroactively, giving effect to the reverse stock split for all periods presented. There was no change to reported net loss in any period presented.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurred net losses of approximately $11,564,000&#160;and $10,713,000&#160;during the years ended December&#160;31, 2020 and 2019, respectively, and has an accumulated deficit of approximately $67,690,000 and $56,126,000<font style="font-size:11pt;">&#160;</font>at December&#160;31, 2020 and 2019, respectively. Cash used in operating activities was approximately $9,033,000<font style="font-size:11pt;">&#160;</font>and $10,342,000<font style="font-size:11pt;">&#160;</font>for the years ended December&#160;31, 2020 and 2019, respectively.&nbsp;&nbsp;The Company has historically funded its operations through financing activities, including raising equity and debt capital.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:10pt;font-family:Times New Roman;">Management&#8217;s operating plans are primarily focused on scaling up its operations, increasing the proportion of patients carrying commercial health insurance with payers that have historically reimbursed for the Company&#8217;s products, and continued work with the Centers for Medicare and Medicaid Services, or CMS, and their billing contractors regarding reimbursement of its products. In addition, the Company believes that it has access to capital resources through payment of a license fee associated with the Company&#8217;s entry into a joint venture and technology license agreement (See Note 13 &#8211; Subsequent Events), possible public or private equity offerings, including usage of its ATM facility (approximately $10 million remaining availability), exercises of outstanding warrants, additional debt financings, or other means.&nbsp;&nbsp;Additional debt financing may contain other terms that are not favorable to the Company or its stockholders. Historical losses, quantitatively, give rise to substantial doubt regarding the Company&#8217;s ability to continue to operate as a going concern. However, based on the company's latitude as to the timing and amount of certain expenses, and its current cash position, the Company believes that the substantial doubt is mitigated as of the issuance date of these financial statements</font>.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company completed a follow-on offering of its common stock, generating net proceeds of approximately $13.5 million. Based upon its expected cash flows and the funds raised in the February 2020 equity offering, as well as proceeds received from exercises of warrants and issuances under the ATM, the Company believes that its available cash will fund its operations for at least the next twelve months from the issuance date of these financial statements. <font style="font-family:Calibri;font-size:11pt;">&#160;</font>&nbsp;&nbsp;</p>
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
3964250
CY2020 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-top:18pt;margin-bottom:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-top:6pt;margin-bottom:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain prior year amounts in research and development and sales and marketing expenses have been reclassified to cost of goods sold to conform with the current year presentation. Certain current liabilities have been reclassified as accounts payable and accrued expenses to conform with the current year presentation.</p>
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from those estimates. The Company&#8217;s estimates include the allowance for doubtful accounts, deferred tax valuation allowances, valuation of stock-based compensation, valuation of embedded derivative liabilities, warranty obligations and reserves for slow-moving inventory.</p>
CY2020Q4 myo Inventory Reserve For Rental Units
InventoryReserveForRentalUnits
17542
CY2019Q4 myo Inventory Reserve For Rental Units
InventoryReserveForRentalUnits
3735
CY2019Q4 myo Inventory Rental Units
InventoryRentalUnits
23418
CY2020Q4 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
125000000
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13500000
CY2020Q4 myo Remaining Availability Under Offerings
RemainingAvailabilityUnderOfferings
10000000
CY2019 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-11510646
CY2020 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2019 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2020 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
180499
CY2019Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
450101
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1843402
CY2019Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
889583
CY2020Q4 myo Professional Fees Accrued Current
ProfessionalFeesAccruedCurrent
92399
CY2019Q4 myo Professional Fees Accrued Current
ProfessionalFeesAccruedCurrent
142804
CY2020Q4 myo Deferred Payroll Taxes Under Cares Act
DeferredPayrollTaxesUnderCARESAct
118060
CY2020Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
119713
CY2019Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
81981
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
494831
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
173981
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2848904
CY2019Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1738450
CY2020 myo Percentage Of Direct Billing Channel Revenue Insures Represent
PercentageOfDirectBillingChannelRevenueInsuresRepresent
0.40
CY2020 myo Income Tax Examination Minimum Likelihood Of Tax Benefits Being Realized Upon Ultimate Settlement
IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponUltimateSettlement
0.50
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3009845
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
222036
CY2020 us-gaap Advertising Expense
AdvertisingExpense
841300
CY2019 us-gaap Advertising Expense
AdvertisingExpense
301700
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
40682
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
46854
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
18000
CY2020Q4 myo Inventory Rental Units
InventoryRentalUnits
62531
CY2020Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
603443
CY2019Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
372996
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
372827
CY2020Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
724656
CY2019Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
443268
CY2019 us-gaap Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
-194485
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
11718319
CY2018Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
3661
CY2019 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
196236
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
382468
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
347249
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
287445
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
192277
CY2019Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
378239
CY2020 myo Payment Against Derivative Liability
PaymentAgainstDerivativeLiability
-255533
CY2020 us-gaap Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
-122706
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
24125
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
6033
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4236
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
3786
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
331
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
21805
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5000
CY2020 myo Share Based Compensation Arrangement By Share Based Payment Award Options Adjustment Due To Reverse Stock Split In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdjustmentDueToReverseStockSplitInPeriod
28
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
123
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
2201
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
421
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
24088
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
13763
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
14998
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
72.6000
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
31.7700
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
69.0200
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
72.9700
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.0500
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
63.0000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.4700
CY2020 myo Share Based Compensation Arrangements By Share Based Payment Award Options Adjustments Due To Reverse Stock Split Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAdjustmentsDueToReverseStockSplitWeightedAverageExercisePrice
63.0000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.0500
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
58.6600
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
80.5500
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
51.2900
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
70.2800
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
68.0300
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M3D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M29D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M3D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M1D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M29D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
157260
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
17581
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
23194
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
17581
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11894
CY2020 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2019 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.73
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
57.37
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.1014
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.6255
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2231
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0054
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0216
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y5M15D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
614302
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
907993
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
169063
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
12113
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
181176
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
2694823
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
48005
CY2020 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
-118835
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2709159
CY2018Q4 myo Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
169063
CY2019 myo Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
12113
CY2019Q4 myo Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
181176
CY2020 myo Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
2694823
CY2020 myo Class Of Warrant Or Rights Expired
ClassOfWarrantOrRightsExpired
48005
CY2020 myo Class Of Warrant Or Rights Exercised
ClassOfWarrantOrRightsExercised
-118835
CY2020Q4 myo Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
2709159
CY2018Q4 myo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
121.50
CY2019 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice
52.50
CY2019Q4 myo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
86.40
CY2020 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice
7.46
CY2020 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice
198.98
CY2020 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice
1.36
CY2020Q4 myo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
7.77
CY2018Q4 myo Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
121.80
CY2019 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePriceExercisable
52.50
CY2019Q4 myo Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
86.40
CY2020 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePriceExercisable
7.46
CY2020 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period Weighted Average Exercise Price Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePriceExercisable
198.98
CY2020 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Exercise Price Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePriceExercisable
1.36
CY2020Q4 myo Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
7.77
CY2020 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
175900
CY2019 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
51700
CY2020Q4 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
44900
CY2019Q4 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
25900
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
457200
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
490500
CY2020Q4 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
29600
CY2019Q4 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
47400
CY2020 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company has a non-cancelable lease agreement for its office space in Fort Worth, TX expiring in 2025 with early termination available at the company’s discretion in 2023. Additionally, the company has a month-to-month lease agreement for office space in Cambridge, MA. Termination options were not included in the lease term for the Company's existing operating lease. Certain of the arrangements have discounted rent periods or escalating rent payment provisions. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheets. We recognize rent expense on a straight-line basis over the lease term.
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
173437
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
48612
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
54638
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
56245
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
57852
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
59459
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
173000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
346000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
14505000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
276806
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
103369
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
9072
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
631433
CY2020 us-gaap Lease Cost
LeaseCost
640505
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y1M6D
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11925000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
14505000
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.20
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2709
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13761000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
11378000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
158000
CY2020 myo Product Warranty Period
ProductWarrantyPeriod
P3Y
CY2016 myo Product Warranty Period
ProductWarrantyPeriod
P1Y
CY2019Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
81981
CY2018Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
92000
CY2020 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
61752
CY2019 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
4174
CY2019 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
29227
CY2020 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
24020
CY2019 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
43420
CY2020Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
119713
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2065000
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2196000
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-515000
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-706000
CY2020 myo Federal State And Local Income Tax Expense Benefit
FederalStateAndLocalIncomeTaxExpenseBenefit
-2580000
CY2019 myo Federal State And Local Income Tax Expense Benefit
FederalStateAndLocalIncomeTaxExpenseBenefit
-2902000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2580000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2902000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0557
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0557
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements State And Local
EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
-0.0048
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements State And Local
EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
0.0122
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies Domestic
EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic
-0.0079
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0299
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0070
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
28000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
28000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
558000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11925000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0
CY2020Q4 myo Operating Loss Carry Forwards Annual Limitations
OperatingLossCarryForwardsAnnualLimitations
281000
CY2020Q4 myo Operating Loss Carryforwards Unutilized
OperatingLossCarryforwardsUnutilized
437000
CY2020Q4 myo Deferred Tax Asset And Valuation Allowance Adjusted To Reflect Federal Nol Unutilized
DeferredTaxAssetAndValuationAllowanceAdjustedToReflectFederalNOLUnutilized
92000
CY2020 myo Operating Loss Carryforwards Limitations On Use Cares Act
OperatingLossCarryforwardsLimitationsOnUseCARESAct
The CARES Act allowed net operating loss incurred in 2018-2020 to be carried back five years or carried forward indefinitely, and to be fully utilized without being subjected to the 80% taxable income limitation. Net operating losses incurred after December 31, 2020 will be subjected to the 80% taxable income limitation.
CY2020 myo Operating Loss Adjustment Description Cares Act
OperatingLossAdjustmentDescriptionCARESAct
net operating loss incurred in 2018-2020 to be carried back five years or carried forward indefinitely
CY2020Q4 myo Operating Loss Carryforwards Subject To Taxable Income Limitation Percentage
OperatingLossCarryforwardsSubjectToTaxableIncomeLimitationPercentage
0.80
CY2020 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2019 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2020Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0

Files In Submission

Name View Source Status
0001564590-21-012068-index-headers.html Edgar Link pending
0001564590-21-012068-index.html Edgar Link pending
0001564590-21-012068.txt Edgar Link pending
0001564590-21-012068-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gxor1cckklla000001.jpg Edgar Link pending
gxor1cckklla000002.jpg Edgar Link pending
gxor1cckklla000003.jpg Edgar Link pending
gxor1cckklla000004.jpg Edgar Link pending
myo-10k_20201231.htm Edgar Link pending
myo-20201231.xml Edgar Link completed
myo-20201231.xsd Edgar Link pending
myo-20201231_cal.xml Edgar Link unprocessable
myo-20201231_def.xml Edgar Link unprocessable
myo-20201231_lab.xml Edgar Link unprocessable
myo-20201231_pre.xml Edgar Link unprocessable
myo-ex1026_347.htm Edgar Link pending
myo-ex21_348.htm Edgar Link pending
myo-ex231_6.htm Edgar Link pending
myo-ex311_7.htm Edgar Link pending
myo-ex312_8.htm Edgar Link pending
myo-ex321_11.htm Edgar Link pending
myo-ex322_9.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending